NCT01027650View on ClinicalTrials.gov

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

February 28, 2013

Conditions
Macular EdemaRetinal Vein Occlusion
Interventions
DRUG

AGN208397 intravitreal injection

AGN208397 intravitreal injection on Day 1.

DRUG

dexamethasone intravitreal implant

Dexamethasone 700 ug intravitreal implant on Day 1.

Trial Locations (5)

Unknown

Phoenix

East Melbourne

London

Tel Aviv

Cape Town

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01027650 - Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO) | Biotech Hunter | Biotech Hunter